Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...

Descripción completa

Detalles Bibliográficos
Autores principales: Ermisch, Michael, Bucsics, Anna, Vella Bonanno, Patricia, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Fürst, Jurij, Garuolienė, Kristina, van der Graaff, Martin, Gulbinovič, Jolanta, Haycox, Alan, Jones, Jan, Joppi, Roberta, Laius, Ott, Langner, Irene, Martin, Antony P., Markovic-Pekovic, Vanda, McCullagh, Laura, Magnusson, Einar, Nilsen, Ellen, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Sauermann, Robert, Schuurman, Ad, Ramos, Ricardo, Vlahovic-Palcevski, Vera, Zara, Corinne, Godman, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://www.ncbi.nlm.nih.gov/pubmed/27733828
http://dx.doi.org/10.3389/fphar.2016.00305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://www.ncbi.nlm.nih.gov/pubmed/27733828
http://dx.doi.org/10.3389/fphar.2016.00305

Ejemplares similares